Pertofrane

Insomnia, Bulimia Nervosa, Panic Disorder + 7 more

Treatment

1 FDA approval

20 Active Studies for Pertofrane

What is Pertofrane

Desipramine

The Generic name of this drug

Treatment Summary

Desipramine hydrochloride is a type of antidepressant medication that works by increasing levels of serotonin and norepinephrine in the brain. It is usually prescribed to treat depression, but can also be used to treat symptoms of agitation and insomnia as well as attention-deficit hyperactivity disorder. While it has fewer side effects than other similar medications, it can still cause sedation, blurred vision, dry mouth, constipation, and urinary retention.

Norpramin

is the brand name

Pertofrane Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Norpramin

Desipramine

1964

122

Approved as Treatment by the FDA

Desipramine, also called Norpramin, is approved by the FDA for 1 uses including Depression .

Depression

Effectiveness

How Pertofrane Affects Patients

Desipramine is a type of antidepressant drug related to muscle relaxants and antipsychotics. It works by blocking chemicals in the brain that affect mood (noradrenaline and serotonin). Desipramine blocks these chemicals more than other types of antidepressant drugs. It also changes the way certain receptors in the brain respond to serotonin. Most people will feel better 2-4 weeks after starting this drug, though some may need up to 8 weeks. People with more severe depression may start to feel better sooner.

How Pertofrane works in the body

Desipramine is a type of antidepressant that helps to increase stimulation in the brain by blocking the reuptake of the neurotransmitters norepinephrine and serotonin. It does this by preventing these chemicals from leaving the space between neurons, allowing them to build up and have a larger effect on the brain. Desipramine also helps to make serotonin more effective, which is thought to be part of why it works as an antidepressant. Finally, it has a mild effect on certain receptors which control muscle movement. All of this works together to help reduce depression symptoms.

When to interrupt dosage

The advised measure of Pertofrane is contingent upon the recognized affliction, including Irritable Bowel Syndrome (IBS), Neuropathic Pain and Chronic Pain. The degree of dosage is indicated in the table below, according to the method of administration.

Condition

Dosage

Administration

Insomnia

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Irritable Bowel Syndrome

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Bulimia Nervosa

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Panic Disorder

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Depression

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Diabetic Neuropathy

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Neuralgia, Postherpetic

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Neuropathic Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Anorexia Nervosa

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Chronic Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Warnings

Pertofrane Contraindications

Condition

Risk Level

Notes

Myocardial Infarction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Pertofrane.

Common Pertofrane Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Desipramine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Desipramine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Desipramine is combined with Aclidinium.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Desipramine.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Desipramine.

Pertofrane Toxicity & Overdose Risk

Desipramine has an LD50 of 290 mg/kg in male mice and 320 mg/kg in female rats. It can cause drowsiness, low blood pressure, dry mouth, trouble seeing, constipation, difficulty urinating, an irregular heartbeat, high blood pressure, and heart failure. It can also cause confusion, memory issues, mania, stomach discomfort, anxiety, trouble sleeping, headaches, and general fatigue. When stopping use of desipramine, withdrawal symptoms may occur.

Pertofrane Novel Uses: Which Conditions Have a Clinical Trial Featuring Pertofrane?

Currently, there are 791 active investigations assessing the effects of Pertofrane in the management of Anorexia Nervosa, Irritable Bowel Syndrome (IBS) and Depression.

Condition

Clinical Trials

Trial Phases

Diabetic Neuropathy

5 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Irritable Bowel Syndrome

5 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1

Panic Disorder

13 Actively Recruiting

Not Applicable

Anorexia Nervosa

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Chronic Pain

0 Actively Recruiting

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Bulimia Nervosa

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Neuralgia, Postherpetic

0 Actively Recruiting

Patient Q&A Section about pertofrane

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug desipramine used for?

"Desipramine is a tricyclic antidepressant that is used to treat depression by increasing the levels of certain natural substances in the brain that are needed for mental balance."

Answered by AI

What is the other name for desipramine?

"Desipramine is a prescription medication that comes in tablet form that is taken orally. It is available under the brand name Norpramin."

Answered by AI

Does desipramine help with anxiety?

"Desipramine is a tricyclic antidepressant that can be used to treat depression, panic, generalized anxiety, and PTSD."

Answered by AI

What is Pertofrane?

"Pertofrane is a brand name for the generic medication Desipramine, which is a non-selective monoamine reuptake inhibitor."

Answered by AI

Clinical Trials for Pertofrane

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Recruiting
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Have you considered Pertofrane clinical trials?

We made a collection of clinical trials featuring Pertofrane, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Pertofrane clinical trials?

We made a collection of clinical trials featuring Pertofrane, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 80
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Waking Up smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Pertofrane clinical trials?

We made a collection of clinical trials featuring Pertofrane, we think they might fit your search criteria.
Go to Trials